Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

97 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Severe Neuro-COVID is associated with peripheral immune signatures, autoimmunity and neurodegeneration: a prospective cross-sectional study.
Etter MM, Martins TA, Kulsvehagen L, Pössnecker E, Duchemin W, Hogan S, Sanabria-Diaz G, Müller J, Chiappini A, Rychen J, Eberhard N, Guzman R, Mariani L, Melie-Garcia L, Keller E, Jelcic I, Pargger H, Siegemund M, Kuhle J, Oechtering J, Eich C, Tzankov A, Matter MS, Uzun S, Yaldizli Ö, Lieb JM, Psychogios MN, Leuzinger K, Hirsch HH, Granziera C, Pröbstel AK, Hutter G. Etter MM, et al. Among authors: yaldizli o. Nat Commun. 2022 Nov 9;13(1):6777. doi: 10.1038/s41467-022-34068-0. Nat Commun. 2022. PMID: 36351919 Free PMC article.
Anti-GABAA receptor encephalitis 14 months after allogeneic haematopoietic stem-cell transplant for acute myeloid leukaemia.
Rusche T, Yaldizli Ö, Galbusera R, Mutke M, Halter JP, Lieb J, Matteazzi F, Stelmes A, Bittner J, Grzonka P, Frank N, Cordier D, Hench J, Frank S, Hirsch HH, Fischer U, Kuhle J, Sutter R, Rüegg S, Fisch U. Rusche T, et al. Among authors: yaldizli o. Lancet. 2024 Feb 3;403(10425):469-470. doi: 10.1016/S0140-6736(23)02831-3. Lancet. 2024. PMID: 38309783 No abstract available.
Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis.
Hauser SL, Bar-Or A, Comi G, Giovannoni G, Hartung HP, Hemmer B, Lublin F, Montalban X, Rammohan KW, Selmaj K, Traboulsee A, Wolinsky JS, Arnold DL, Klingelschmitt G, Masterman D, Fontoura P, Belachew S, Chin P, Mairon N, Garren H, Kappos L; OPERA I and OPERA II Clinical Investigators. Hauser SL, et al. N Engl J Med. 2017 Jan 19;376(3):221-234. doi: 10.1056/NEJMoa1601277. Epub 2016 Dec 21. N Engl J Med. 2017. PMID: 28002679 Free article. Clinical Trial.
Escalating to medium- versus high-efficacy disease modifying therapy after low-efficacy treatment in relapsing remitting multiple sclerosis.
Müller J, Roos I, Kalincik T, Lorscheider J, Galli E, Benkert P, Schädelin S, Sharmin S, Einsiedler M, Hänni P, Schmid J, Kuhle J, Derfuss T, Granziera C, Ziemssen T, Siepmann T, Yaldizli Ö. Müller J, et al. Among authors: yaldizli o. Brain Behav. 2024 May;14(5):e3498. doi: 10.1002/brb3.3498. Brain Behav. 2024. PMID: 38688877 Free PMC article.
Use of pragmatic randomized trials in multiple sclerosis: A systematic overview.
Hirt J, Janiaud P, Düblin P, Nicoletti GJ, Dembowska K, Nguyen TVT, Woelfle T, Axfors C, Yaldizli Ö, Granziera C, Kuhle J, Kappos L, Hemkens LG. Hirt J, et al. Among authors: yaldizli o. Mult Scler. 2024 Apr;30(4-5):463-478. doi: 10.1177/13524585231221938. Epub 2024 Jan 22. Mult Scler. 2024. PMID: 38253528 Free PMC article. Review.
Evaluation of frequency, severity, and independent risk factors for recurrence of disease activity after fingolimod discontinuation in a large real-world cohort of patients with multiple sclerosis.
Cerdá-Fuertes N, Nagy S, Schaedelin S, Sinnecker T, Ruberte E, Papadopoulou A, Würfel J, Kuhle J, Yaldizli Ö, Kappos L, Derfuss T, Décard BF. Cerdá-Fuertes N, et al. Among authors: yaldizli o. Ther Adv Neurol Disord. 2023 Feb 6;16:17562864221150312. doi: 10.1177/17562864221150312. eCollection 2023. Ther Adv Neurol Disord. 2023. PMID: 36762317 Free PMC article.
97 results